• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    September 24, 2024 - FDA Roundup: September 24, 2024

    9/24/24 4:08:17 PM ET
    $RS
    Metal Fabrications
    Industrials
    Get the next $RS alert in real time by email
    For Immediate Release:
    September 24, 2024

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, the FDA held a ribbon-cutting ceremony to highlight the completion of the 64,000 square foot expansion and renovation of the National Forensic Chemistry Center (NFCC)  located in Cincinnati, Ohio.  The goal of this revitalization effort was to improve FDA’s mission readiness nationally and help attract and retain highly qualified employees. The NFCC is a specialty laboratory that serves as the FDA’s national forensic laboratory providing specialized laboratory services in analytical chemistry and molecular/ microbiology related to adulteration/contamination, counterfeiting, and product tampering of FDA regulated commodities including drugs, dietary supplements, foods, cosmetics, veterinary feeds, and medical devices.
    • On Monday, the FDA issued a safety advisory cautioning pet owners that samples of two Answers Pet Food products made by Lystn LLC tested positive for Salmonella, a third product tested positive for Listeria monocytogenes (L. mono), and a fourth product tested positive for Salmonella and L. mono. The FDA collected and tested unopened retail samples of products after receiving three consumer complaints of illness in dogs that ate the products. The affected products are sold frozen in 4-pound (half-gallon) cartons and consist of certain batches of Answers Pet Food Raw Beef Detailed Formula for Dogs, Answers Pet Food Raw Beef Straight Formula for Dogs, and Answers Pet Food Straight Chicken Formula for Dogs. Information to help consumers identify affected batches of product can be found in the Product Information section of the advisory. These products should not be fed to pets.
    • On Friday, the FDA approved isatuximab-irfc (Sarclisa) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).  The most common adverse reactions (≥20%) were upper respiratory tract infection, diarrhea, fatigue, peripheral sensory neuropathy, pneumonia, musculoskeletal pain, cataract, constipation, peripheral edema, rash, infusion-related reaction, insomnia, and COVID-19 infection. Full prescribing information for Sarclisa will be posted on Drugs@FDA.
    • On Friday, the FDA issued a safety advisory cautioning pet owners that FDA samples of five Darwin’s Natural Pet Products raw cat and dog food made by Arrow Reliance, Inc. tested positive for Salmonella and a sixth FDA sample tested positive for Salmonella and L. mono. Affected products are sold in frozen 2-pound packages and consist of certain lots of Darwin’s Natural Selections Antibiotic & Grain-Free Chicken Recipe for Cats and Darwin’s Natural Selections Antibiotic & Grain-Free Chicken Recipe for Dogs. These product lots should not be fed to pets. For specific product information and to learn about potential signs of illness, see the FDA Advisory.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

    Get the next $RS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RS

    DatePrice TargetRatingAnalyst
    1/8/2025Underperform → Peer Perform
    Wolfe Research
    12/2/2024$341.00Neutral
    Goldman
    7/26/2024$262.00Peer Perform → Underperform
    Wolfe Research
    4/11/2024$380.00Buy → Neutral
    Citigroup
    4/28/2023Outperform → Peer Perform
    Wolfe Research
    1/4/2023$231.00Neutral
    BofA Securities
    10/6/2022$218.00 → $201.00Buy → Neutral
    Goldman
    8/15/2022$230.00Outperform
    BMO Capital Markets
    More analyst ratings

    $RS
    SEC Filings

    See more
    • SEC Form 11-K filed by Reliance Inc.

      11-K - RELIANCE, INC. (0000861884) (Filer)

      6/17/25 4:37:13 PM ET
      $RS
      Metal Fabrications
      Industrials
    • SEC Form 11-K filed by Reliance Inc.

      11-K - RELIANCE, INC. (0000861884) (Filer)

      6/17/25 4:34:58 PM ET
      $RS
      Metal Fabrications
      Industrials
    • SEC Form 144 filed by Reliance Inc.

      144 - RELIANCE, INC. (0000861884) (Subject)

      5/30/25 5:11:50 PM ET
      $RS
      Metal Fabrications
      Industrials

    $RS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcevoy Robert Ambrose was granted 567 shares, increasing direct ownership by 3% to 22,814 units (SEC Form 4)

      4 - RELIANCE, INC. (0000861884) (Issuer)

      5/22/25 5:57:44 PM ET
      $RS
      Metal Fabrications
      Industrials
    • Director Baldwin Lisa was granted 567 shares, increasing direct ownership by 14% to 4,659 units (SEC Form 4)

      4 - RELIANCE, INC. (0000861884) (Issuer)

      5/22/25 5:57:19 PM ET
      $RS
      Metal Fabrications
      Industrials
    • Director Colonias Karen Winifred was granted 567 shares (SEC Form 4)

      4 - RELIANCE, INC. (0000861884) (Issuer)

      5/22/25 5:56:38 PM ET
      $RS
      Metal Fabrications
      Industrials

    $RS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 24, 2024 - FDA Roundup: September 24, 2024

      For Immediate Release: September 24, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA held a ribbon-cutting ceremony to highlight the completion of the 64,000 square foot expansion and renovation of the National Forensic Chemistry Center (NFCC)  located in Cincinnati, Ohio.  The goal of this revitalization effort was to impro

      9/24/24 4:08:17 PM ET
      $RS
      Metal Fabrications
      Industrials

    $RS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Reliance, Inc. upgraded by Wolfe Research

      Wolfe Research upgraded Reliance, Inc. from Underperform to Peer Perform

      1/8/25 8:26:24 AM ET
      $RS
      Metal Fabrications
      Industrials
    • Goldman initiated coverage on Reliance, Inc. with a new price target

      Goldman initiated coverage of Reliance, Inc. with a rating of Neutral and set a new price target of $341.00

      12/2/24 8:18:40 AM ET
      $RS
      Metal Fabrications
      Industrials
    • Reliance, Inc. downgraded by Wolfe Research with a new price target

      Wolfe Research downgraded Reliance, Inc. from Peer Perform to Underperform and set a new price target of $262.00

      7/26/24 7:44:23 AM ET
      $RS
      Metal Fabrications
      Industrials